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Background & Aims: There is an unclear association between intake of fish and long-chain 
n-3 polyunsaturated fatty acids (n-3 LC-PUFAs) and colorectal cancer (CRC). We examined 
the association between fish consumption, dietary and circulating levels of n-3 LC-PUFAs, 
and ratio of n-6:n-3 LC-PUFA with CRC using data from the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort. 
 
Methods: Dietary intake of fish (total, fatty/oily, lean/white) and n-3 LC-PUFA were 
estimated by food frequency questionnaires given to 521,324 participants in the EPIC study; 
among these, 6291 individuals developed CRC (median follow up, 14.9 years). Levels of 
phospholipid LC-PUFA were measured by gas chromatogr phy in plasma samples from a 
sub-group of 461 CRC cases and 461 matched individuals without CRC (controls). 
Multivariable Cox proportional hazards and conditional logistic regression models were used 
to calculate hazard ratios (HRs) and odds ratios (ORs), respectively, with 95% CIs.  
 
Results: Total intake of fish (HR for quintile 5 vs 1, 0.88; 95% CI, 0.80–0.96; Ptrend=.005), 
fatty fish (HR for quintile 5 vs 1, 0.90; 95% CI, 0.82–0.98; Ptrend=.009), and lean fish (HR for 
quintile 5 vs 1, 0.91; 95% CI, 0.83–1.00; Ptrend=.016) were inversely associated with CRC 
incidence. Intake of total n-3 LC-PUFA (HR for quintile 5 vs 1, 0.86; 95% CI, 0.78–0.95; 
Ptrend=.010) was also associated with reduced risk of CRC, whereas dietary ratio of n-6:n-3 
LC-PUFA was associated with increased risk of CRC (HR for quintile 5 vs 1, 1.31;  95% CI, 
1.18–1.45; Ptrend<.001). Plasma levels of phospholipid n-3 LC-PUFA was not associated with 

















Conclusions: In an analysis of dietary patterns of participants i  the EPIC study, we found 
regular consumption of fish, at recommended levels, to be associated with a lower risk of 
CRC, possibly through exposure to n-3 LC-PUFA. Levels of n-3 LC-PUFA in plasma were 
not associated with CRC risk, but there may be differences in risk at different regions of the 
colon. 
 
















What you need to know 
Background: Dietary intake of fish might reduce risk of colorectal cancer, possibly through 
exposure to marine n-3 fatty acids. Epidemiology studies have not provided a consensus view 
on the link between fatty acids from seafood and colorectal cancer. 
 
Findings: In an analysis of data from more than 500,000 participants in the European 
Prospective Investigation into Cancer and Nutrition cohort, we associated intake of fish, at 
levels recommended by World Health Organization, with reduced risk of colorectal cancer. 
The potential effect of fish consumption on colorectal tumorigenesis might be mediated by 
specific fatty acids in seafood. There might be differences in effect on risk in different 
regions of the colon. 
 
Implications for patient care: Consumption of fish appears to reduce the risk of colorectal 


















Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally with an 
estimated 1.8 million new cases in 20181. Established lifestyle and dietary risk factors for
CRC include smoking, alcohol consumption, obesity, physical inactivity, high red and 
processed meat consumption, and low intake of fibre2. The World Cancer Research Fund 
(WCRF) concluded, based on a meta-analysis of  eighteen prospective studies, that there was 
“limited but suggestive” evidence that fish decreases CRC risk3. Nevertheless, there is still 
uncertainty whether fish consumption is beneficial for CRC prevention and how consumption 
of different fish types (e.g. fatty/oily, white/lean) relates to CRC risk.  
Fatty/oily fish is the near exclusive dietary source of long-chain n-3 polyunsaturated 
fatty acids (n-3 LC-PUFA). In animal4 and in vitro5 models, n-3 LC-PUFAs have been shown 
to have pro-apoptotic and anti-proliferative properties on colon tumour cells. Human studies 
that have investigated the association between dietary intake of n-3 LC-PUFA and CRC risk 
have generally shown inverse relationships with possible differences by sex, study 
population, duration of follow-up, and tumour characteristics including location, stage and 
molecular features6-11. Two meta-analyses of prospective studies showed an inverse 
association between n-3 LC-PUFA intake and CRC in men, in proximal colon cancer, and 
with extended follow-up period whereas null or even positive associations were observed for 
distal colon cancer and in Asian men6, 7. Dietary n-3 LC-PUFA has also been inversely 
associated with risk of microsatellite instability (MSI)-high CRC but not with microsatellite 
stable tumors9. In addition, the association of marine n-3 LC-PUFA with CRC risk has been 
shown to vary depending on the presence of tumor-infiltrating T-cells12. 
  For circulating biomarker studies, the associations f plasma levels of n-3 LC-PUFA 
with CRC have shown inconsistent results, ranging from null13, 14 to weak inverse 















up periods15. Alternatively, it has been proposed that the balance between n-6 and n-3 PUFA 
may be more relevant for health outcomes than the absolute intake of n-3 LC-PUFA, as a 
consequence of their divergent metabolic effects on inflammation17. Overall, previous studies 
on the role of n-3 LC-PUFA and CRC incidence remain inconclusive. Thus, further 
prospective studies in different populations are neded to clarify the association between n-3 
LC-PUFAs, their relative balance with n-6 LC-PUFA, their metabolism, and CRC risk. 
In this study, we undertook a comprehensive investigation of how fish consumption, 
and dietary and circulating levels of n-3 LC-PUFA as well as n-6:n-3 LC-PUFA ratio were 
associated with CRC risk in the European Prospectiv In estigation into Cancer and Nutrition 
(EPIC), a large multi-country prospective cohort wih over 520,000 participants and wide 
variation in fish intake. A prior analysis conducted within EPIC reported inverse associations 
between fish consumption and CRC risk18. Here, we performed additional analyses that 
included both dietary and circulating n-3 LC-PUFA, with an additional 11 years of follow-up 
and almost 5-fold higher number of incident cases. 
 
Methods 
Study participants  
EPIC is a prospective cohort of 521,324 participants, recruited between 1992 and 2000 in 23 
centres located in 10 European countries (Denmark, F ance, Germany, Greece, Italy, 
Netherlands, Norway, Spain, Sweden, UK)19. Anthropometric measures, lifestyle and dietary 
intake were collected at recruitment. Blood samples w re also collected and stored at the 
International Agency for Research on Cancer (IARC), or in local biobanks. Ethical approval 
was obtained from the review boards pertaining to IARC and to the respective recruiting 
centres. Informed consent was obtained from all the participants. Our analysis excluded 















(n=25,184), missing dietary data (n=6,259), or within 1% highest/lowest energy intake vs 
requirement (n=9,573). Our final cohort analysis included 476,160 participants (142,241 men 
and 333,919 women). 
 
Lifestyle, anthropometry and diet 
Body weight and height were measured by a trained nurse in the majority of EPIC centres or 
were self-reported. Questionnaires were used to obtain information on education, smoking 
and physical activity. Dietary intake was assessed at recruitment by validated centre-specific 
questionnaires. Fish and fish products (excluding fsh oil supplements) included fatty/oily 
(fat>4%/weight; e.g. salmon) and lean/white fish (fat≤4%/weight; e.g. cod). Shellfish (e.g. 
prawn) intake was considered separately or combined with fish as “total fish and shellfish”.  
Dietary intakes of LC-PUFAs were estimated using the United States Department of 
Agriculture (USDA) Nutrient Database, Release 20 (https://ndb.nal.usda.gov/ndb/). The 
USDA database was previously matched with the EPIC food list to expand the EPIC Nutrient 
Database (ENDB) with extra food components. We alsoestimated total n-3 LC-PUFA (sum 
of eicosapentaenoic, EPA; docosapentaenoic, DPA; and docosahexaenoic, DHA) and n-6:n-3 
LC-PUFA ratio (arachidonic+di-homo-γ-linolenic/n-3 LC-PUFA).  
 
Follow-up and vital status  
Incident CRC cases were identified through regional cancer registries or via a combination of 
methods, including health insurance records, pathology registries, and active follow-up of 
participants and relatives. CRC cases were defined according to the International 
Classification of Diseases for Oncology (ICD-O): proximal colon (C18.0-C18.5: cecum, 















(C18.6-C18.7: descending and sigmoid colon), rectum (C19: recto-sigmoid junction, C20: 
rectum). 
 
Sub-study of circulating PUFAs and CRC 
Pre-diagnostic plasma samples from 461 incident CRC cases and 461 matched controls from 
seven countries were included in a nested case-control analysis of circulating n-3 LC-PUFAs 
and CRC.  Controls were selected by incidence density sampling from all cohort members 
alive and free of cancer at the time of diagnosis of the index case. Cases and controls were 
matched by centre, sex, blood collection details including time (±2-4 hours interval), age (±6 
months-<±2 years), fasting status (<3/3-6 hours) and mong women by menopausal status, 
and among premenopausal women, by phase of menstrual cycle and hormone replacement 
therapy use.   
 
Measurements of plasma phospholipid fatty acids 
Plasma phospholipid levels of LC-PUFAs were determined by gas chromatography using a 
method previously described20. Briefly, total lipids were extracted from plasma s mples by 
chloroform-methanol 2:1 (v/v). Phospholipids were purified by adsorption chromatography 
on silica tubes. Fatty acid methyl esters (FAMEs) were formed by transmethylation with 
Methyl-Prep II (Alltech, Deerfield, USA). Analyses were carried out on the gas 
chromatograph 7890A (Agilent Technologies, USA). The individual LC-PUFAs were 
separated and identified by comparison of their respective retention time with those of 
purchased standard methyl ester fatty acids. Plasma phospholipid LC-PUFAs were expressed 


















Full prospective cohort 
Socio-demographic and dietary intake variables in the EPIC population are presented 
separately for cases and non-cases, and compared using Wilcoxon rank-sum and χ2 tests for 
continuous and categorical variables, respectively.  Supplementary Table 1 presents 
Spearman correlation matrix for fish intake, fatty acids and other potential confounding 
variables. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 
95% confidence intervals (CI) for the association between fish intake, dietary n-3 LC-PUFA, 
and CRC risk in the full EPIC cohort. Time at study entry was age at recruitment and exit 
time was age at whichever of the following came first: CRC diagnosis, death, emigration, or 
completed follow-up. Models were stratified by age at recruitment (1-year categories), sex, 
and centre. Analyses were run with fish and dietary n-3 LC-PUFA intakes in quintiles or as 
continuous variables for intakes of 100g/day of fish3, 100mg/day of n-3 LC-PUFA, and 5-
point increment of n-6:n-3 LC-PUFA. The distribution f shellfish consumption did not allow 
the categorisation by quintiles, but by tertiles. We additionally evaluated the association with 
CRC risk considering the recommendation by the World Health Organisation which is to 
consume 1-2 servings (100-150g/serving) of fish weekly21. For all the analyses, 
proportionality was evaluated using the slope of Schoenfeld residuals over time, which 
showed no deviation from the proportional hazards assumption. All the models were adjusted 
for risk factors a priori associated with CRC: as continuous variables, body mass index 
(BMI), height, intakes of alcohol, red and processed meat, fibre, dairy products, and as 
categorical variables (Table 1) physical activity, smoking, and education. Variables with 
missing data (<5%) were coded as distinct categories. Trends tests were performed using 
median values of categories as continuous. Multiplicative interaction was assessed by 















evaluated using the Wald test. Separate analyses were also conducted by sex, and anatomical 
subtypes of CRC. To evaluate the possible impact of reverse causation, we re-ran the 
analyses with cases diagnosed within the first two years of follow-up excluded. 
 
Nested case-control biomarker sub-study 
In the sub-study of circulating n-3 LC-PUFAs and CRC risk, multivariable conditional 
logistic regression was used to compute odds ratios (OR) and 95%CI for the associations 
between circulating levels of n-3 LC-PUFAs and CRC. Participants were divided into 
quartiles based on the distributions in the control g up. Analyses were adjusted for the same 
covariates as in the analyses for dietary intakes. Subsite analyses were run for proximal and 
distal colon, but not for rectum, due to few number of cases (n=5). Two-sided P-values <0.05 
were considered statistically significant.  
 
Results 
After a median follow-up time of 14.9 years, 6,291 incident cases of CRC (2,719 men and 
3,572 women) were diagnosed. Of these cases, 4,197 were colon cancers whereas 2,094 cases 
were rectal cancer cases. Compared to non-cases, cases were more likely to be current or 
former smokers, and higher consumers of red and processed meats and alcohol (Table 1). 
 
Dietary fish consumption and CRC 
Table 2 summarizes the associations between fish intake and the risk for CRC. Overall, total 
fish intake was inversely associated with CRC (HR comparing extreme quintiles 
HRQ5vs.Q1=0.88, 95%CI=0.80-0.96, Ptrend=0.005) and particularly colon cancer 
(HRQ5vs.Q1=0.89, 95%CI=0.79-1.00, Ptrend=0.024). The inverse associations were observed for 















not reach the threshold of significance (Table 2). Both fatty fish and lean fish intakes were 
inversely associated with CRC and specifically, colon cancer (Table 2). By anatomic 
location, there was no difference between men and women in the association between fish 
intake and the risk for CRC (P for heterogeneity>0.05) (Supplementary figure 1). Shellfish 
intake was not associated with CRC risk, but total fish intake combined with shellfish intake 
was inversely associated with the risk for CRC (Supplementary Table 2). Compliance with 
WHO’s recommendation for fish intake (1-2 servings/week of 100g each) was associated 
with a 7% lower risk of CRC, compared to <1 serving/week (Supplementary Figure 2). There 
was no overall difference in the association of fish intake and CRC by country 
(Pheterogeneity=0.12) (Supplementary Figure 3).  
 
Dietary n-3 LC-PUFA intake and CRC 
Dietary intake of total n-3 LC-PUFA was inversely associated with the risk for CRC 
(HRQ5vs.Q1=0.86, 95%CI=0.78-0.95, Ptrend=0.010) and specifically colon (HRQ5vs.Q1=0.85, 
95%CI=0.75-0.96, Ptrend=0.038), but not rectal cancer (Table 3). All indivi ual n-3 LC-PUFA 
(EPA, DPA, and DHA) were significantly inversely associated with CRC risk (Table 3). The 
n-6:n-3 LC-PUFA ratio was associated with higher CRC risk (HRQ5vs.Q1=1.31, 95%CI=1.18-
1.45, Ptrend<0.001), colon (HRQ5vs.Q1=1.32, 95%CI=1.17-1.50, Ptrend<0.001), and rectal cancer 
(HRQ5vs.Q1=1.24, 95%CI=1.04-1.48, Ptrend=0.020). Although no significant differences in the 
associations between estimates of EPA, DPA, DHA and total n-3 LC-PUFA, and CRC was 
observed between men and women (P for heterogeneity >0.05), the risk estimates only 
reached statistical significance in women (Supplementary Figure 4). In sensitivity analyses 
excluding cases diagnosed during the first 2 years of follow-up (n=781 cases excluded for the 
analysis), the results were generally unchanged (data not shown). Similar associations 















consumption, red and processed meats, or physical activity (data not shown, all P for 
interactions>0.05). 
 
Sub-study of circulating PUFAs and CRC 
The associations between plasma phospholipid EPA, DPA, and DHA, total n-3 LC-PUFA, n-
6:n-3 LC-PUFA and CRC risk were not statistically significant (Table 4). However, an 
inverse trend was observed for proximal (OR quantile 4 vs 1 of n-3 LC-PUFA levels 
ORQ4vs.Q1=0.55, 95%CI=0.27-1.11) compared to distal colon cancer (ORQ4vs.Q1=1.54, 
95%CI=0.77-3.08) (Pheterogeneity=0.026). The results did not change by BMI, or smoking 
status, or when cases diagnosed within 2 years of foll w-up were excluded (data not shown).  
 
Discussion  
In this prospective analysis of approximately half a million participants, we found that intakes 
total fish including fatty fish, lean fish and shellfish were inversely associated with CRC risk. 
Overall, weekly intake of 100-200g of fatty or lean fish was associated with a 7% lower CRC 
risk. Similarly, dietary intakes of all n-3 LC-PUFA were inversely associated with the risk for 
CRC while the n-6:n-3 LC-PUFA ratio was positively associated with CRC. On the other 
hand, circulating levels of n-3 LC-PUFA were not associated with CRC risk in a sub-study.  
Our observed inverse association between fish consumption and CRC is consistent 
with the WCRF meta-analysis that reported that 100g/day increment intake of total fish was 
associated with an 11% lower risk of CRC (HR=0.89, 95%CI=0.80-0.99)3. However, in that 
meta-analysis, the inverse association was only apparent in men (HR=0.83, 95%CI=0.71-
0.98) and not in women (HR=0.96, 95%CI=0.82-1.12). We found inverse associations 
between both fatty and lean fish intakes and CRC risk, which suggests that fish consumption 















The biological mechanisms through which fish consumption potentially lowers CRC 
risk are not fully understood. Fatty/oily fish are primary sources of n-3 LC-PUFAs which 
may inhibit cancer development through the production of eicosanoids that possess anti-
inflammatory properties17. Although fat content is lower in lean/white fish compared to fatty 
fish, lean fish could be a non-negligible source of n-3 LC-PUFAs. In fact, the overall 
composition of fish with respect to n-3 LC-PUFA conte t depends not only on the amount of 
total fat, but also on the percentage of fatty acids; for example sole-like lean fish with less 
than 1.7% total fat has approximately 24.6% (as a proportion of total fatty acids) of EPA and 
DHA, while herring which contains 12.7% of total fat has 12% of EPA and DHA22. The n-3 
LC-PUFAs produce anti-inflammatory five-series leukotrienes and three-series 
prostaglandins, and act as competitive inhibitors of the actions of the n-6 LC-PUFAs; the 
latter lead to the production of four-series leukotrienes and two-series prostaglandins and 
promote the synthesis of pro-inflammatory interleukins and tumour necrosis factor17. In 
agreement with this hypothesis, our study showed that the n-6:n-3 LC-PUFA ratio in the diet 
is positively associated with CRC risk. We additionally observed that fatty fish intake was 
significantly inversely associated with proximal coon cancer, whereas lean fish intake tended 
to be inversely associated with distal colon cancer. In addition to exposure to n-3 LC-PUFAs, 
the associations we observed for both fatty and lean fish and CRC may be due to a 
combination of diverse nutritional factors derived from fish in general, including vitamins D 
and B12, selenium, or particular amino-acids
23. 
In our population we observed 14% lower CRC risk comparing those in the lowest vs 
highest quintiles of intake of n-3 LC-PUFA. The inverse association between dietary n-3 LC-
PUFAs and CRC risk observed in our study did not differ between men and women, albeit 
the risk estimates only attained statistical signifcance in women (potentially due to the higher 















dietary intake of n-3 LC-PUFAs might decrease the risk of CRC, regardless of sex. Of note, 
we did not find any association between circulating n-3 LC-PUFAs and the risk for CRC.  
Interestingly, we observed an inverse trend between circulating n-3 LC-PUFA and 
risk for proximal colon cancer compared with distal colon cancer, which is in agreement with 
previous findings7. Since the proximal and distal colon have different mbryologic origins, 
divergent functions and invariably display distinct molecular features9, it has been 
hypothesized that cancers that arise across the sub-locations could have different aetiologies. 
At a physiological level, as faecal matter moves from the proximal colon towards the distal 
colon and rectum, the concentration of electrolytes, bile acids and other residues of digestion 
changes with continuous absorption of water, which influences the diversity and genus of 
microbes along the colon. Elevated levels of n-3 LC-PUFA in the proximal colon may 
stimulate increased production of short-chain fatty acids, which have been suggested to 
decrease the risk for CRC through lowering of inflammation in the colon24. Further 
experimental research is needed to investigate why the effects of n-3 LC-PUFA may differ on 
the proximal vs distal colon. 
The current analysis represents the largest study to date to comprehensively 
investigate the association between fish and n-3 LC-PUFA intakes and CRC risk. The large 
number of incident CRC cases allowed analyses by sex and tumour location, and the detailed 
phenotypic information collected from all participants permitted careful adjustment for 
known CRC risk factors. A limitation of our study is that dietary intake information was only 
available from baseline (recruitment) while dietary habits of the EPIC participants may have 
changed over the follow-up period. Nevertheless, intakes of fish and other food items 
reported at recruitment were generally reliable over time, when compared with two repeated 
dietary questionnaires and 12 consecutive monthly 24-hour dietary recalls administered to a 















information on fish oil supplement intake. An investigation of a subgroup of EPIC 
participants showed that use of vitamin and micronutrient supplements was common26. Fish 
oil use was not specifically explored; hence unmeasured effects of supplementation may have 
influenced the risk for CRC in our analysis. Finally, although we adjusted for a 
comprehensive set of covariates, and we conducted numerous sensitivity analyses, potential 
unmeasured and residual confounding cannot be excluded. 
In conclusion, our data suggest that fish intake, and dietary intake of individual and 
total n-3 LC-PUFA may lower the risk for CRC. Finally, this study showed that an 
imbalanced ratio of n-6:n-3 LC-PUFA from the diet was associated with an increased risk of 
CRC. Our analysis makes a substantial contribution to the growing body of evidence linking 
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Table 1: Selected baseline demographic and lifestyl characteristics of study participants by 
colorectal cancer status, EPIC cohort study, 1992-2014 
 Colorectal cancer 
cases (n=6291) 
Non-cases 
(n=469 869)  
P-value* 
Men, % 43.2 29.7   <0.001 
Age at recruitment, years, mean±SD 57.3±7.87 51.2±9.95 <0.001 
Follow-up, years, mean±SD 9.22±4.73 14.0±4.0 <0.001 
Age at diagnosis, years, mean±SD 66.5±10.2 - - 
    
Anthropometry    
Body mass index, kg/m2, mean±SD 26.4±4.26 25.4±4.30 <0.001 
    
Socio-economic status and lifestyle    
Education status   <0.001 
     None 4.72 4.45  
     Primary school 32.1 25.9  
     Technical or professional  25.2 22.5  
     Secondary school  15.6 20.8  
     Higher education 19.0 24.2  
Smoking status   <0.001 
     Never 37.2 43.2  
     Current, 1 to <16cigarettes/day 11.0 11.6  
     Current, 16-<26 cigarettes/day 6.29 6.23  
     Current, >26  cigarettes/day 1.72 1.82  















     Former, quit 11-<20 years 10.1 8.14  
     Former, quit >20 years 11.8 7.83  
     Current, pipe-cigar-occasional 8.28 8.42  
Physical activity status   <0.001 
     Inactive  24.9 20.9  
     Moderately inactive 32.5 32.9  
     Moderately active 22.5 26.4  
     Active  18.4 17.9  
Alcohol consumption   <0.001 
     None 6.39 5.67  
     <5  g/day 35.4 41.9  
     5 to <14.9  g/day 25.7 27.0  
     15.0 to <29.9  g/day 14.7 13.8  
     >30  g/day 17.8 12.0  
    
Dietary intake, g/day, mean±SD    
Red and processed meat 83.3±56.3 74.9±52.7 <0.001 
Fibre 22.7±8.04 22.9±8.14 0.107 
Dairy products 333.7±245.1 326.5±235.4 0.166 
Total fish and shellfish 39.0±35.3 37.1±35.7 <0.001 
Total fish 35.1±33.6 33.6±34.6 <0.001 
Fatty fish 13.2±16.7 11.8±15.6 <0.001 
Lean fish  18.0±23.6 17.3±24.6 <0.001 
Shellfish 3.13±5.61 3.03±5.57 <0.001 















Frequencies may not add up to 100% due to missing data 
* Using Wilcoxon rank-sum and χ2 tests 
†Geometric means (95% confidence intervals)  
    
n-3 long-chain polyunsaturated 
fatty acids (n-3 LC-PUFA) 
   
Dietary intakes, mg/day, mean±SD    
Eicosapentaenoic acid (EPA) 129±160 114±152 <0.001 
Docosapentaenoic acid (DPA) 30±29 29.0±30.2 <0.001 
Docosahexaenoic acid (DHA) 196±228 178±163.5 <0.001 
n-3 LC-PUFA (EPA+DPA+DHA) 355±413 321±401 <0.001 
Ratio n-6:n-3 LC-PUFA 0.26±0.40 0.26±1.29 0.022 
    
Plasma phospholipid, % of total 
fatty acids† 
n=461 n=461  
Eicosapentaenoic acid (EPA) 0.92 (0.87-0.96) 0.93 (0.88-
0.97) 
0.731 
Docosapentaenoic acid (DPA) 0.90 (0.89-0.92) 0.91 (0.89-
0.93) 
0.738 
Docosahexaenoic acid (DHA) 4.53 (4.41-4.66) 4.58 (4.45-
4.70) 
0.778 
n-3 LC-PUFA (EPA+DPA+DHA) 6.55 (6.38-6.72) 6.61 (6.45-
6.78) 
0.626 

















Table 2: Hazard ratios (HRs)* and 95% confidence int rvals (95%CI) for colorectal cancer risk associated with dietary fish intake (quintiles and 
continuous), EPIC cohort study, 1992-2014 
 Quintiles of fish intake    
 Q1 Q2 Q3 Q4 Q5 Ptrend Pheterog
eneity 
Continuous§ 
Total fish, g/day <9.07 9.07-<19.0 19.0-<30.9 30.9-51.3 >51.3    
Colorectal cancer         
Cases 1178 1129 1271 1364 1349    
HR(95%CI) 1.00  0.92 (0.85-1.00) 0.93 (0.85-1.01) 0.88 (0.80-0.96) 0.88 (0.80-0.96) 0.005  0.90 (0.82-0.98) 
    Colon cancer         
    Cases 751 762 813 884 870    
    HR(95%CI) 1.00  0.96  (0.87-1.06) 0.92 (0.83-1.03) 0.89 (0.80-0.99) 0.89 (0.79-1.00) .024 0.506† 0.90 (0.80-1.01) 
        Proximal colon 
cancer 
        
        Cases 359 368 353 409 388    















        Distal colon cancer         
        Cases 315 306 365 358 399    
        HR(95%CI) 1.00  0.91 (0.77-1.06) 0.96 (0.82-1.13) 0.84 (0.71-0.99) 0.89 (0.75-1.07) 0.145  0.95 (0.80-1.12) 
    Rectal cancer         
    Cases 399 349 436 452 458    
    HR(95%CI) 1.00  0.87 (0.75-1.01) 0.98 (0.84-1.13) 0.87 (0.75-1.02) 0.88 (0.75-1.04) 0.181  0.91 (0.77-1.07) 
         
Fatty fish, g/day <1.0 1.0-<4.36 4.36-<9.13 9.13-17.7 >17.7    
Colorectal cancer         
Cases 1165 1076 1241 1358 1451    
HR(95%CI) 1.00  1.00 (0.92-1.09) 0.95 (0.88-1.04) 0.95 (0.88-1.04) 0.90 (0.82-0.98) 0.009  0.84 (0.71-1.00) 
    Colon cancer         
    Cases 768 693 816 875 928    
    HR(95%CI) 1.00  0.99 (0.89-1.10) 0.94 (0.85-1.05) 0.92 (0.83-1.03) 0.89 (0.80-0.99) 0.022 0.199† 0.88 (0.71-1.09) 
        Proximal colon 
cancer 















        Cases 386 310 386 408 387    
        HR(95%CI) 1.00  0.96 (0.82-1.12) 0.95 (0.82-1.09) 0.93 (0.80-1.08) 0.81 (0.70-0.95) 0.018 0.096‡ 0.76 (0.55-1.04) 
        Distal colon cancer         
        Cases 307 298 336 361 441    
        HR(95%CI) 1.00  1.07 (0.91-1.26) 0.98 (0.84-1.15) 0.95 (0.80-1.11) 1.03 (0.87-1.21) 0.856  1.11 (0.83-1.50) 
    Rectal cancer         
    Cases 373 358 402 464 497    
    HR(95%CI) 1.00  1.04 (0.89-1.20) 0.99 (0.86-1.14) 1.05 (0.91-1.21) 0.91 (0.78-1.06) 0.330  0.80 (0.59-1.07) 
         
Lean fish, g/day <0.74 0.74-<6.45 6.45-<13.9 13.9-26.5 >26.5    
Colorectal cancer         
Cases 1148 1144 1260 1426 1313    
HR(95%CI) 1.00  0.99 (0.91-1.09) 0.93 (0.85-1.02) 0.91 (0.83-0.99) 0.91 (0.83-1.00) 0.016  0.92 (0.80-1.05) 
    Colon cancer         
    Cases 742 761 804 914 859    















        Proximal colon 
cancer 
        
        Cases 355 343 360 416 403    
        HR(95%CI) 1.00  1.00 (0.85-1.18) 0.91 (0.77-1.07) 0.88 (0.76-1.03) 0.95 (0.80-1.12) 0.263 0.902‡ 1.00 (0.78-1.26) 
        Distal colon cancer         
        Cases 322 335 329 392 365    
        HR(95%CI) 1.00  1.08 (0.91-1.28) 0.89 (0.75-1.06) 0.93 (0.79-1.09) 0.85 (0.71-1.01) 0.038  0.80 (0.61-1.03) 
    Rectal cancer         
    Cases 383 364 434 480 433    
    HR(95%CI) 1.00  0.97 (0.83-1.13) 1.01 (0.87-1.18) 0.96 (0.82-1.11) 0.96 (0.82-1.13) 0.555  0.98 (0.78-1.24) 
*Adjusted for BMI, height, physical activity, smoking, education, and intakes of energy, alcohol, red and processed meat, fibre, dairy products 
and stratified by age, sex, and centre  
†Colon vs rectum 

















Table 3: Hazard ratios (HRs)* and 95% confidence int rvals (CI) for colorectal cancer risk associated with dietary n-3 long-chain 
polyunsaturated fatty acids estimates (quintiles and continuous), EPIC cohort study, 1992-2014 
 Quintiles of n-3 long-chain  polyunsaturated fatty acids intake (n-3 LC-PUFA)   





<23.5 23.5-<49.0 49.0-<84.5 84.5-164.6 >164.6    
Colorectal cancer         
Cases 1161 1129 1082 1299 1620    
HR(95%CI) 1.00  0.93 (0.86-1.02) 0.88 (0.80-0.96) 0.92 (0.84-1.01) 0.86 (0.78-0.95) 0.008  0.97 (0.95-0.99) 
    Colon cancer         
    Cases 753 747 704 850 1026    
    HR(95%CI) 1.00  0.94 (0.85-1.05) 0.86 (0.77-0.97) 0.93 (0.83-1.04) 0.87 (0.77-0.98) 0.033 0.189† 0.97 (0.95-0.99) 
        Proximal colon cancer         
        Cases  359 345 333 404 436    















        Distal colon cancer         
        Cases 317 305 297 343 481    
        HR(95%CI) 1.00  0.92 (0.78-1.08) 0.83 (0.70-0.98) 0.87 (0.73-1.03) 0.94 (0.78-1.13) 0.435  0.99 (0.96-1.03) 
     Rectal cancer         
     Cases 385 355 360 430 564    
     HR(95%CI) 1.00  0.91 (0.79-1.06) 0.91 (0.78-1.06) 0.93 (0.79-1.09) 0.87 (0.74-1.04) 0.212  0.98 (0.95-1.02) 
         
Docosapentaenoic acid 
(DPA), mg/day 
<9.30 9.30-<16.6 16.6-<25.3 25.3-41.3 >41.3    
Colorectal cancer         
Cases 1039 1241 1348 1327 1336    
HR(95%CI) 1.00  0.96 (0.88-1.05) 0.95 (0.87-1.04) 0.91 (0.82-1.00) 0.83 (0.75-0.92) <0.00
1 
 0.84 (0.76-0.94) 
    Colon cancer         
    Cases 674 838 891 821 856    
















       Proximal colon cancer         
       Cases  320 386 422 367 382    
        HR(95%CI) 1.00  0.97 (0.83-1.14) 0.97 (0.82-1.14) 0.90 (0.76-1.08) 0.85 (0.71-1.03) 0.069 0.398‡ 0.82 (0.67-1.00) 
        Distal colon cancer         
        Cases  276 360 366 349 392    
        HR(95%CI) 1.00  0.94 (0.80-1.11) 0.88 (0.74-1.05) 0.81 (0.68-0.97) 0.82 (0.68-1.00) 0.017  0.92 (0.76-1.12) 
    Rectal cancer         
    Cases 341 381 434 486 452    
    HR(95%CI) 1.00  0.94 (0.81-1.10) 0.98 (0.84-1.15) 1.00 (0.85-1.18) 0.84 (0.71-1.01) 0.172  0.86 (0.72-1.04) 
         
Docosahexaenoic acid 
(DHA), mg/day 
<42.1 42.1-<84.0 84.0-<140 140-264 >264    
Colorectal cancer         
Cases  1141 1109 1145 1350 1546    















    Colon cancer         
    Cases 731 730 762 884 973    
    HR(95%CI) 1.00  0.92 (0.83-1.03) 0.92 (0.82-1.03) 0.94 (0.84-1.06) 0.87 (0.77-0.99) 0.084 0.261† 0.98 (0.96-1.00) 
        Proximal colon cancer         
        Cases 358 338 354 408 419    
        HR(95%CI) 1.00  0.93 (0.79-1.08) 0.94 (0.80-1.10) 1.02 (0.86-1.21) 0.89 (0.74-1.06) 0.450 0.189‡ 0.97 (0.95-1.00) 
        Distal colon cancer         
        Cases 303 294 327 370 449    
        HR(95%CI) 1.00  0.88 (0.74-1.04) 0.91 (0.77-1.09) 0.88 (0.74-1.05) 0.89 (0.74-1.08) 0.353  1.00 (0.97-1.02) 
    Rectal cancer         
    Cases 383 359 361 448 543    
    HR(95%CI) 1.00  0.90 (0.78-1.05) 0.89 (0.76-1.04) 0.91 (0.77-1.07) 0.87 (0.73-1.04) 0.201  0.99 (0.97-1.01) 



















Colorectal cancer         
Cases 1150 1116 1128 1321 1576    
HR(95%CI) 1.00  0.91 (0.84-1.00) 0.89 (0.81-0.97) 0.91 (0.83-1.00) 0.86 (0.78-0.95) 0.010  0.99 (0.98-1.00) 
    Colon cancer         
    Cases 746 727 740 874 993    
    HR(95%CI) 1.00  0.90 (0.81-1.01) 0.89 (0.80-1.00) 0.93 (0.83-1.04) 0.85 (0.75-0.96) 0.038 0.142† 0.99 (0.98-1.00) 
       Proximal colon cancer         
       Cases 358 335 353 409 422    
        HR(95%CI) 1.00  0.93 (0.79-1.08) 0.96 (0.81-1. 2) 1.04 (0.88-1.23) 0.86 (0.72-1.04) 0.386 0.236‡ 0.99 (0.97-1.00) 
        Distal colon cancer         
       Cases 316 296 308 357 466    
        HR(95%CI) 1.00  0.84 (0.71-0.99) 0.84 (0.71-1.00) 0.82 (0.69-0.98) 0.86 (0.72-1.04) 0.182  1.00 (0.98-1.01) 
    Rectal cancer         
    Cases 377 348 381 434 554    
    HR(95%CI) 1.00  0.94 (0.81-1.09) 0.91 (0.78-1.06) 0.90 (0.76-1.06) 0.91 (0.77-1.08) 0.277  0.99 (0.98-1.01) 















n-6:n-3 LC-PUFA <0.05 0.05-<0.10 0.10-<0.18 0.18-0.36 >0.36    
Colorectal cancer         
Cases 1306 1322 1213 1180 1270    
HR(95%CI) 1.00  1.13 (1.04-1.23) 1.19 (1.09-1.30) 1.20 (1.09-1.32) 1.31 (1.18-1.45) <0.00
1 
 1.06 (1.04-1.09) 
    Colon cancer         
    Cases 746 727 740 874 993    
    HR(95%CI) 1.00  1.14 (1.03-1.26) 1.23 (1.10-1.37) 1.21 (1.08-1.37) 1.32 (1.17-1.50) <0.00
1 
0.991† 1.06 (1.03-1.10) 
        Proximal colon cancer         
        Cases 358 335 353 409 422    
        HR(95%CI) 1.00  1.14 (0.97-1.33) 1.22 (1.03-1.45) 1.32 (1.11-1.58) 1.39 (1.15-1.68) <0.00
1 
0.046‡ 1.08 (1.04-1.13) 
        Distal colon cancer         
        Cases 316 296 308 357 466    















    Rectal cancer         
    Cases 377 348 381 434 554    
    HR(95%CI) 1.00  1.09 (0.95-1.26) 1.12 (0.96-1.31) 1.17 (0.99-1.38) 1.24 (1.04-1.48) 0.020  1.05 (1.01-1.09) 
*Adjusted for BMI, height, physical activity, smoking, education, and intakes of energy, alcohol, red and processed meat, fibre, dairy products 
and stratified by age, sex, and centre  
†Colon vs rectum 
‡Proximal vs distal colon  


















Table 4: Odds ratios* and 95% confidence intervals (CI) for colorectal cancer risk associated with plasm  phospholipid n-3 long-chain 
polyunsaturated fatty acids (Quantiles and continuous), EPIC cohort study, 1992-2014  
 Quantiles of plasma phospholipid of n-3 long-chain 
polyunsaturated fatty acids (n-3 LC-PUFA) 
   
 Q1 Q2 Q3 Q4 Ptrend Pheterogeneity
† Continuous, per 
unit increase 
Eicosapentaenoic acid (EPA)        
Colorectal cancer        
Cases 124 105 124 108    
OR(95%CI) 1.00  0.79 (0.53-1.18) 0.92 (0.62-1.37) 0.89 (0.59-
1.35) 
0.745  0.93 (0.71-1.23) 
    Colon cancer        
    Cases 122 103 124 106    
    OR(95%CI) 1.00  0.78 (0.53-1.17) 0.94 (0.63-1.40) 0.89 (0.59-
1.35) 
0.762  0.93 (0.70-1.22) 















      Cases 54 45 41 45    
      OR(95%CI) 1.00  0.89 (0.46-1.70) 0.74 (0.38-1.42) 0.79 (0.41-
1.50) 
0.403 0.146 0.88 (0.57-1.36) 
      Distal colon cancer        
      Cases 52 51 70 49    
      OR(95%CI) 1.00  0.75 (0.40-1.41) 1.31 (0.68-2.52) 1.00 (0.50-
2.00) 
0.580  1.03 (0.65-1.64) 
Docosapentaenoic acid (DPA)        
Colorectal cancer         
Cases  131 101 105 124    
OR(95%CI) 1.00  0.70 (0.46-1.07) 0.82 (0.54-1.24) 1.18 (0.73-
1.91) 
0.542  0.99 (0.49-2.00) 
    Colon cancer        
    Cases 129 100 103 123    
    OR(95%CI) 1.00  0.72 (0.47-1.10) 0.83 (0.55-1.26) 1.18 (0.73-
1.92) 















      Proximal colon cancer        
      Cases 55 39 33 58    
      OR(95%CI) 1.00  0.73 (0.36-1.49) 0.48 (0.23-1.02) 0.99 (0.44-
2.22) 
0.700 0.176 0.85 (0.27-2.68) 
      Distal colon cancer        
      Cases  56 51 60 55    
      OR(95%CI) 1.00  1.21 (0.63-2.33) 1.62 (0.86-3.05) 1.75 (0.83-
3.68) 
0.080  1.35 (0.44-4.15) 
Docosahexaenoic acid (DHA)        
Colorectal cancer        
Cases  126 104 118 113    
OR(95%CI) 1.00  1.11 (0.75-1.61) 1.02 (0.68-1.52) 1.19 (0.76-
1.85) 
0.573  1.03 (0.60-1.75) 
    Colon cancer        
    Cases  124 103 118 110    
















      Proximal colon cancer        
      Cases 52 40 48 45    
      OR(95%CI) 1.00  0.65 (0.35-1.21) 0.81 (0.40-1.62) 0.75 (0.37-
1.53) 
0.528 0.050 0.78 (0.32-1.87) 
      Distal colon cancer        
      Cases 59 49 60 54    
      OR(95%CI) 1.00  1.71 (0.93-3.13) 1.89 (1.01-3.55) 1.92 (0.93-
3.94) 
0.058  1.64 (0.72-3.78) 
n-3 LC-PUFA 
(EPA+DPA+DHA)  
       
Colorectal cancer cases         
Cases  135 93 120 113    
OR(95%CI) 1.00  0.74 (0.50-1.09) 0.98 (0.66-1.48) 0.94 (0.61-
1.44) 
0.999  0.98 (0.56-1.72) 















    Cases 133 92 119 111    
    OR(95%CI) 1.00  0.72 (0.49-1.07) 0.97 (0.64-1.46) 0.94 (0.61-
1.44) 
0.999  0.98 (0.56-1.72) 
      Proximal colon cancer        
      Cases 56 37 46 46    
      OR(95%CI) 1.00  0.44 (0.23-0.85) 0.66 (0.33-1. 4) 0.55 (0.27-
1.11) 
0.195 0.026 0.76 (0.31-1.82) 
      Distal colon cancer        
      Cases 65 40 63 54    
      OR(95%CI) 1.00  0.86 (0.46-1.58) 1.55 (0.83-2.90) 1.54 (0.77-
3.08) 
0.122  1.59 (0.64-3.95) 
n-6:n-3 LC-PUFA‡        
Colorectal cancer         
Cases 119 120 105 117    
OR(95%CI) 1.00  0.92 (0.62-1.37) 0.86 (0.56-1.32) 0.87 (0.55-
1.36) 















    Colon cancer        
    Cases 117 120 105 113    
    OR(95%CI) 1.00  0.93 (0.62-1.38) 0.85 (0.56-1.31) 0.86 (0.55-
1.35) 
0.479  0.88 (0.55-1.40) 
      Proximal colon cancer        
      Cases 48 52 44 41    
      OR(95%CI) 1.00  0.78 (0.39-1.54) 0.77 (0.37-1.60) 0.74 (0.33-
1.64) 
0.498 0.633 0.97 (0.45-2.09) 
      Distal colon cancer        
      Cases 57 61 47 57    
     OR(95%CI) 1.00  1.21 (0.66-2.22) 0.69 (0.35-1.35) 0.69 (0.35-
1.36) 
0.150  0.63 (0.30-1.32) 
*Adjusted for BMI, height, physical activity, smoking, education, and intakes of energy, alcohol, red and processed meat, fibre, dairy products 

















Supplementary figures  
 
S1: Hazard ratios, per 100 g/day increment (continuous), and 95% confidence interval for colorectal cancer risk associated with fish intake, by 
sex 
Risk associations were estimated by multivariate Cox proportional hazard models. No heterogeneity was observed between men and women, 
fatty fish and lean fish intake, or colorectal cancer subtypes. 
 
S2: Hazard ratios, per servings/week of types of fish, and 95% confidence interval for colorectal cancer risk associated with recommended 
intakes of fish 
Risk associations were estimated by multivariate Cox pr portional hazard models. The intake of 1 to 2 servings of fish/week as recommended by 
WHO, was associated with a decrease in colorectal cancer risk.  
 
S3: Hazard ratios and 95% confidence interval for colorectal cancer risk, by EPIC country 
Hazard ratios per colorectal cancer risk were estimated for each EPIC participating country, using multivariate Cox proportional hazard models. 
















S4: Hazard ratios and 95% confidence interval for colorectal cancer risk associated with dietary n-3 LC-PUFA, by sex 
Hazard ratios for colorectal cancer risk, per 100 mg per day increment for individual and grouping of n-3 LC-PUFA and 5-unit increment in n-
6:n-3 LC-PUFA, were estimated by multivariate Cox proportional hazard models. No heterogeneity was observed between men and women, 
































Total fish 1             
Fatty fish  0.738 1            
Lean fish  0.728 0.478 1           
EPA* 0.855 0.789 0.490 1          
DPA* 0.817 0.715 0.446 0.904 1         
DHA* 0.890 0.789 0.531 0.980 0.913 1        
n-3 LC-PUFA* 0.881 0.790 0.514 0.991 0.929 0.996 1       
n-6/n-3 LC-
PUFA* 
-0.675 -0.609 -0.456 -0.784 -0.603 -0.768 -0.761 1      
BMI 0.067 0.032 0.048 0.080 0.028 0.081 0.077 -0.087 1     
Alcohol  0.049 0.113 -0.039 0.124 0.135 0.110 0.120 -0.003 -0.013 1    
Red and 
processed meat  
0.142 0.172 0.093 0.217 0.292 0.216 0.230 0.081 0.160 0.234 1   
Physical activity 0.006 0.038 0.031 0.049 0.060 0.035 0.042 0.001 -0.119 0.104 0.063 1  
Education  -0.047 -0.023 -0.056 -0.083 -0.011 -0.088 -0.080 0.135 -0.292 0.134 -0.102 0.071 1 
Smoking  0.053 0.068 0.026 0.067 0.098 0.069 0.072 -0.012 -0.023 0.183 0.118 0.050 0.073 
*Dietary estimates  













Supplementary table 1: Hazard ratios (HRs)* and 95% confidence intervals (95% CI) for colorectal cancer risk associated with shellfish and combined 
shellfish and fish intake (quintiles and tertiles and continuous) , EPIC cohort study, 1992-2014 
 Quintiles of shellfish and fish intake and tertiles of shellfish intake  
 Q1 Q2 Q3 Q4 Q5 Ptrend Continuous, per 
100g/day  
Total fish and shellfish 
intake, g/day 
<10.4 10.4-<21.2 21.2-<34.2 34.2-56.1 >56.1   
Colorectal cancer cases 1148 1181 1262 1361 1339   
Colorectal cancer 1.00 (Ref.) 0.95 (0.87-1.03) 0.92 (0.84-1.00) 0.89 (0.81-0.97) 0.87 (0.79-0.96) 0.003 0.90 (0.82-0.98) 
Colon cancer 1.00 (Ref.) 1.00 (0.90-1.11) 0.91 (0.82-1.02) 0.89 (0.80-1.00) 0.89 (0.79-1.00) 0.014 0.90 (0.80-1.01) 
Proximal colon cancer 1.00 (Ref.) 0.98 (0.83-1.15) 0.94 (0.79-1.11) 0.85 (0.71-1.01) 0.92 (0.77-1.11) 0.165 0.90 (0.76-1.07) 
Distal colon cancer 1.00 (Ref.) 1.09 (0.93-1.26) 0.93 (0.79-1.09) 0.98 (0.83-1.15) 0.91 (0.76-1.09) 0.173 0.95 (0.80-1.12) 
Rectal cancer 1.00 (Ref.) 0.89 (0.77-1.03) 0.96 (0.83-1.12) 0.91 (0.78-1.06) 0.88 (0.75-1.05) 0.240 0.91 (0.77-1.07) 
 Tertile 1 Tertile 2 Tertile 3     
Shellfish intake, g/day 0 >0-2.94 >2.95     
Colorectal cancer cases 1883 2320 2088 - -   
Colorectal cancer 1.00 (Ref.) 1.01 (0.94-1.10) 1.00 (0.93-1.08) - - 0.950 1.23 (0.76-1.99) 













Proximal colon cancer 1.00 (Ref.) 1.09 (0.94-1.27) 1.06 (0.92-1.22) - - 0.572 1.22 (0.49-3.05) 
Distal colon cancer 1.00 (Ref.) 1.03 (0.89-1.19) 1.04 (0.91-1.20) - - 0.543 1.67 (0.73-3.80) 
Rectal cancer 1.00 (Ref.) 0.94 (0.82-1.09) 0.97 (0.85-1.11) - - 0.790 1.23 (0.54-2.80) 
* Adjusted for BMI, height, physical activity, smoking, education, and intakes of energy, alcohol, red and processed meat, fibre, dairy products and stratified 
by age, sex, and centre 
